NYMXF
NYMOX PHARMACEUTICAL CORPPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
Signal stack
Where each data set points today.
- TrendUPTREND
64% above its 50-day average.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 0 bullish · 2 bearish · 3 neutral- BEARISH 20-FSep 14, 2026
Nymox Pharmaceutical's FY2025 20-F reveals a pre-revenue biopharma with a going-concern…
This filing confirms Nymox is in a critical liquidity crisis with no revenue, minimal cash, and a going-concern warning. The death of the primary lender (James G. Robinson) creates extreme…
- NEUTRAL 6-KAug 31, 2026
Nymox Pharmaceutical Corp filed a 6-K reporting the results of a special shareholder meeting held…
This is a routine governance filing with no financial or strategic content. No trading action is warranted; monitor future filings for operating updates or pipeline developments.
- NEUTRAL 6-KAug 7, 2026
Nymox is calling a special shareholder meeting on August 28, 2026 to elect five directors (versus…
The special meeting is routine governance — expanding the board from two to five directors. The delayed 20-F filing is the main risk signal; monitor whether the delay extends past EDGAR filing…
- BEARISH 6-KJun 3, 2026
Nymox Pharmaceutical provided an update on its drug Nymozarfex (TM) for BPH. The initial US…
The drug's regulatory path in both the US and EU has suffered significant setbacks, with no clear path to approval without new financing. Traders should monitor for any capital raise announcements…
All NYMXF filing & press-release reports (5)
- 20-F reportSep 14, 2026
- 6-K reportAug 31, 2026
- 6-K reportAug 7, 2026
- 6-K reportJun 3, 2026
- 6-K reportMar 27, 2026